ES2182357T3 - Nueva utilizacion de budesonide y formoterol. - Google Patents

Nueva utilizacion de budesonide y formoterol.

Info

Publication number
ES2182357T3
ES2182357T3 ES98944373T ES98944373T ES2182357T3 ES 2182357 T3 ES2182357 T3 ES 2182357T3 ES 98944373 T ES98944373 T ES 98944373T ES 98944373 T ES98944373 T ES 98944373T ES 2182357 T3 ES2182357 T3 ES 2182357T3
Authority
ES
Spain
Prior art keywords
formoterol
budesonide
new use
active ingredient
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98944373T
Other languages
English (en)
Spanish (es)
Inventor
Carl-Axel Bauer
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2182357(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2182357T3 publication Critical patent/ES2182357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES98944373T 1997-09-19 1998-09-09 Nueva utilizacion de budesonide y formoterol. Expired - Lifetime ES2182357T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
ES2182357T3 true ES2182357T3 (es) 2003-03-01

Family

ID=20408325

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98944373T Expired - Lifetime ES2182357T3 (es) 1997-09-19 1998-09-09 Nueva utilizacion de budesonide y formoterol.
ES02001670T Expired - Lifetime ES2266322T3 (es) 1997-09-19 1998-09-09 Nuevo uso de budesonida y formoterol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02001670T Expired - Lifetime ES2266322T3 (es) 1997-09-19 1998-09-09 Nuevo uso de budesonida y formoterol.

Country Status (38)

Country Link
US (2) US7897646B2 (enExample)
EP (2) EP1014993B1 (enExample)
JP (1) JP2001517630A (enExample)
KR (1) KR20010024140A (enExample)
CN (1) CN1149998C (enExample)
AR (1) AR013506A1 (enExample)
AT (2) ATE329599T1 (enExample)
AU (1) AU757235B2 (enExample)
BR (1) BR9812325A (enExample)
CA (1) CA2302700C (enExample)
CY (1) CY1106156T1 (enExample)
CZ (1) CZ295250B6 (enExample)
DE (2) DE69807239T2 (enExample)
DK (2) DK1210943T3 (enExample)
EE (1) EE04297B1 (enExample)
ES (2) ES2182357T3 (enExample)
HK (1) HK1045812B (enExample)
HU (1) HUP0003848A2 (enExample)
ID (1) ID24838A (enExample)
IL (1) IL134773A (enExample)
IN (1) IN190791B (enExample)
IS (1) IS2715B (enExample)
MX (1) MXPA00002615A (enExample)
MY (1) MY127812A (enExample)
NO (1) NO327176B1 (enExample)
NZ (1) NZ503173A (enExample)
PL (1) PL190782B1 (enExample)
PT (2) PT1014993E (enExample)
RU (1) RU2199322C2 (enExample)
SA (1) SA98190773B1 (enExample)
SE (1) SE9703407D0 (enExample)
SI (2) SI1210943T1 (enExample)
SK (1) SK285330B6 (enExample)
TR (1) TR200000726T2 (enExample)
TW (1) TW546140B (enExample)
UA (1) UA72446C2 (enExample)
WO (1) WO1999015182A1 (enExample)
ZA (1) ZA988516B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ATE369121T1 (de) * 2001-02-06 2007-08-15 Innovata Biomed Ltd Bimodale trockenpulverzusammensetzung zur inhalation
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1921919B1 (en) 2005-07-14 2012-04-04 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX393243B (es) 2009-05-29 2025-03-24 Pearl Therapeutics Inc Composición farmacéutica que comprende la combinación de albuterol y budesónida, adaptada para el suministro respiratorio mediante un inhalador de dosis medida y el uso de las mismas para el tratamiento de trastornos pulmonares.
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
CA2786618C (en) * 2010-01-15 2016-04-12 Lithera, Inc. Lyophilized cake formulations
CA2815374A1 (en) 2010-11-24 2012-06-07 Lithera, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
KR102275109B1 (ko) 2013-03-15 2021-07-07 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
CA3103679A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DK0416950T3 (da) 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
ES2236757T3 (es) * 1995-11-24 2005-07-16 Glaxosmithkline S.P.A. Derivados de quinolina.
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
TR199903272T2 (xx) 1997-06-27 2000-08-21 Astra Aktiebolag Ast�m kar��t� ila�lar�n yeni bile�imleri.
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
SE9703407D0 (sv) 1997-09-19
BR9812325A (pt) 2000-09-05
IS5407A (is) 2000-03-15
PT1014993E (pt) 2002-12-31
CA2302700C (en) 2010-11-23
MY127812A (en) 2006-12-29
HUP0003848A2 (hu) 2001-08-28
EE200000145A (et) 2001-02-15
DE69807239T2 (de) 2003-04-10
ATE222106T1 (de) 2002-08-15
NZ503173A (en) 2001-08-31
PL339295A1 (en) 2000-12-04
US20110097282A1 (en) 2011-04-28
NO20001401D0 (no) 2000-03-17
IL134773A (en) 2005-03-20
US8461211B2 (en) 2013-06-11
CA2302700A1 (en) 1999-04-01
DK1210943T3 (da) 2006-09-18
EP1014993A1 (en) 2000-07-05
SK285330B6 (sk) 2006-11-03
US7897646B2 (en) 2011-03-01
TR200000726T2 (tr) 2000-09-21
DE69834955D1 (de) 2006-07-27
HK1045812A1 (en) 2002-12-13
EP1210943B1 (en) 2006-06-14
AU757235B2 (en) 2003-02-06
SK3892000A3 (en) 2000-12-11
WO1999015182A1 (en) 1999-04-01
ID24838A (id) 2000-08-24
CZ2000950A3 (cs) 2000-06-14
AR013506A1 (es) 2000-12-27
SI1014993T1 (en) 2003-02-28
PL190782B1 (pl) 2006-01-31
CN1271287A (zh) 2000-10-25
US20020042404A1 (en) 2002-04-11
AU9192898A (en) 1999-04-12
CY1106156T1 (el) 2011-06-08
US20060189587A9 (en) 2006-08-24
UA72446C2 (uk) 2005-03-15
NO20001401L (no) 2000-03-17
EP1014993B1 (en) 2002-08-14
IS2715B (is) 2011-02-15
JP2001517630A (ja) 2001-10-09
SA98190773B1 (ar) 2006-10-02
PT1210943E (pt) 2006-09-29
DE69807239D1 (de) 2002-09-19
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
DK1014993T3 (da) 2002-11-11
IN190791B (enExample) 2003-08-23
SI1210943T1 (sl) 2006-10-31
EP1210943A1 (en) 2002-06-05
IL134773A0 (en) 2001-04-30
MXPA00002615A (es) 2002-04-24
ZA988516B (en) 1999-03-19
NO327176B1 (no) 2009-05-04
HK1045812B (en) 2006-12-22
CZ295250B6 (cs) 2005-06-15
EE04297B1 (et) 2004-06-15
CN1149998C (zh) 2004-05-19
ATE329599T1 (de) 2006-07-15
TW546140B (en) 2003-08-11
ES2266322T3 (es) 2007-03-01
DE69834955T2 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
GT199800126A (es) Terapia de combinacion.
ES2159591T3 (es) Composicion de liberacion controlada.
SE9603669D0 (sv) New combination
FI971776L (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ID27504A (id) Formulasi oral baru
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
DE69932510D1 (de) Vaskularisierungsinhibitoren
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
NO992564L (no) Anvendelsen av blandinger av aktive bestanddeler for fremstilling av hypokolesterinemiske midler
ES2089357T3 (es) Formulacion medicinal en forma de aerosol.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
TR199700735T1 (xx) �ste�e g�re azt,DD1 ya da DDC ile birlikte ters transkritaz inhibit�r� 3T ve HIV proteaz inhibit�r� indinavirin kullan�lmas�yla HIV enfeksiyoun i�in bir arada terapi.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ES2131482A1 (es) Formulacion acuosa de bambuterol.
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
RU96115480A (ru) Лекарственное средство, обладающее холелитолитическим действием
DE50006094D1 (de) Neue flüssigformulierungen
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.